Category: Cephalosporin Antibiotics Business

  • Novartis to Acquire GSK’s Cephalosporin Antibiotics Business

    Shots: GSK to receive $350M at closing, along with ~$150M as milestones. The transaction is expected to close in H2’21 The transaction will allow GSK to prioritize and simplify its portfolio and invest in the company’s R&D pipeline and new product launches The agreement includes the global rights to three established brands (Zinnat, Zinacef and […]